ADHD drug delivery specialist Cingulate hit with manufacturing-related FDA rejection

After submitting its timed-release version of a decades-old ADHD drug to the FDA nearly a year ago, Kansas City's Cingulate has suffered a setback in its bid to commercialize its first product.&nbs Cingulate will need to take a detour to win its first FDA approval, as the agency has rejected its lead candidate over manufacturing concerns. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources Podcasts Fierce…

Source: FiercePharma